Therefore, we aimed to identify whether changes in PEPCK-M activity influence the ability of these cells to undergo entosis using pharmacology (iPEPCK-2) and gain-of-function breast carcinoma cell models (L-PCK2). The gene discussed is PCK2; the disease is breast carcinoma.